Placenta Growth Factor drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Ophthalmology, Oncology, and Metabolic Disorders which include the indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Solid Tumor, Metastatic Colorectal Cancer, and Non-Proliferative Diabetic Retinopathy (NPDR). It also reviews key players involved in Placenta Growth Factor targeted therapeutics development with respective active and dormant or discontinued products.

The Placenta Growth Factor pipeline targets constitutes close to 35 molecules. Out of which, approximately 35 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery, and Unknown stages are 5, 1, 15, 7, 5, 3, 10, 6, and 2 respectively.

Placenta Growth Factor overview

Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

For a complete picture of Placenta Growth Factor’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.